Ribavirin1

1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide

spinqualitylabelsall models Ribavirin PDB 4pb1 Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Overview Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C by inhibiting the synthesis of viral RNA. Structure & Function Comparison of the 2D structure of ribavirin to the structures of the nucleoside guanosine and a similiar anti-viral drug viramidine. Ribavirin 4pb1 Protein Interaction Ribavirin with RNA-dependent RNA polymerase Virally-encoded RNA-dependent RNA polymerase (RdRp) is critical for successful viral replication. The incorporation of nucleoside analogs, such as Ribavirin, by RdRp have been shown to induce error in viral replication Ribavirin attaches to the binding pocket, which is comprised of tyrosine at position 344 and aspartic acid at positions 250, 346, and 347. The incorporation of Ribavirin into the RNA results in base-pairing with uracil or cytosine, which increases the mutation rate and leads to viral death. Ribavirin with 3SFU 3sfu Ribavirin with CNT2 Nucleoside transporters facilitate the transport of nucleosides across cell membranes to be used in protein synthesis. Concentrated NTs (CNTs) use the energy of ion gradients for active transportation , while equilibrative NTs (ENTs) transport nucleosides passively down their concentration gradient. Ribavirin is a substrate of ENT1, ENT2, and CNT2. CNT2 binds to the ribose of the ribavirin via hydrogen bonding involving glutamic acid at position 332, asparagine at position 368, and serine at position 371. Ribavirin with 4PB1 (4pb1) Disease Hepatitis C Hepatitis C is an infectious disease that affects the liver due to the Hepatitis C virus (HCV). This disease can be acute or chronic and can even lead to death. By binding to the gC1qR receptor, HCV proteins are able to effectively inhibit the differentiation of helper T cells. In addition, HCV core proteins work by preventing the synthesis of the antiviral interferon IFN-γ. Thus, weakening the body’s immunity and making it susceptible to infection. Ribavirin is used in combination with peginterferon to treat Hepatitis C. By adding pegylated interferon-alpha to ribavirin, the drug had a longer half-life, which required only single weekly dosing for Hepatitis C treatment. There are two types of polyethylene glycol (PEG):1. P-INFa-2b and 2. P-INFa-2a. While P-INFa-2b is linear, covalently attached to histidine, and subject to hydrolysis upon injection, P-INFa-2a is branched, attached to lysine through amide bonds, and circulates as a whole molecule upon injection. The limited distribution of P-INFa-2a results in a longer half-life. Pneumonia Respiratory syncytial virus is responsible for viral pneumonia. This infection causes the air sacs in one or both of the lungs to become inflamed and potentially filled with fluid or pus. In infants, children, and adults over the age of 65, pneumonia can be deadly. It has been shown that Ribavirin can treat viral pneumonia by preventing transcription of respiratory syncytial virus. Mechanism Ribavirin, when administered in combination with pegylated interferon alpha, induces an antiviral state in host cells, resulting in reduced virus replication rates and activation of the host immune system. It is thought that Ribavirin acts as an antiviral agent by disrupting viral RNA synthesis, which would impact both transcription and genome replication in the Hepatitis C virus. However, the exact mechanism by which the drug interferes with this process is unknown. Several theories have been proposed to explain the effect of Ribavirin in inhibiting the replication of the Hepatitis C virus . Immunomodulation by Ribavirin may be responsible for the drug’s antiviral properties. It has been suggested that the natural CD4+ helper T cell response may be altered in the presence of Ribavirin. It is thought that ribavirin may enhance the T helper 1 response, resulting in greater clearance of virus . However, there is conflicting evidence suggesting that the T helper 2 response may be implicated in this process instead . Another possible mechanism involves the enhancement of interferon-stimulated gene (ISG) expression by Ribavirin. When a cell becomes infected with a virus, it may release interferons. Interferons are signaling molecules that function in a paracrine fashion to induce an antiviral state in neighboring cells, protecting them from infection. Ribavirin is thought to enhance the interferon signaling pathway , resulting in a wider antiviral response. This theory has been supported in studies using cell culture models . It has also been suggested that the relationship between Ribavirin and inosine 5’-monophosphate dehydrogenase (IMPDH) may impact the virus RNA synthesis. IMPDH plays a significant role in the guanine nucleotide synthesis pathway. It results in the conversion of inosine 5’-monophosphate to xanthine 5’-monophosphate, which is an intermediate for the nucleotide guanosine . Therefore, modulation of IMPDH activity affects a cell’s reservoir of guanosine. Ribavirin has been shown to function as a competitive inhibitor for IMPDH . Because guanosine triphosphate (GTP) plays a critical role in the viral genome replication process, inhibition of IMPDH would result in the prevention of viral replication. Ribavirin has also been shown to act as an inhibitor for eIF4E, a protein of the translation initiation complex . Because of its structural similarity to guanosine, it mimics the 7-methyl guanosine mRNA cap, preventing translation of viral mRNA. This would result in reduced capacity for viral replication within an infected cell. The Hepatitis C viral genome is replicated by RNA-dependent RNA polymerase (RdRp). A modified form of Ribavirin, Ribavirin 5’-triphosphate (RTP) is also believed to directly inhibit RdRp activity , resulting in lower rates of genome replication. If Ribavirin is converted to the monophosphate form, RMP, it is believed to be incorporated into the viral genome, functioning as a mutagen.

References

1. Gish, R. G. Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy. 2005, November 17;1-6. doi:10.1093/jac/dki405
2. Thomas, E., Ghany, M., Liang, J., The application and mechanism of action of ribavirin in therapy of hepatitis C. Antiviral Chemistry & Chemotherapy 23:1-12 (2012)doi: 10.3851/IMP2125
3. Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology. 2008;47 (1), 306-320. doi: 10.1002/hep.22070
4. Paeshuyse, J, Dallmeier, K, Neyts, J. Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Current Opinion in Virology. 2011;1(6) 590-598. doi: 10.1016/j.coviro.2011.10.030
5. National Heart, Lung and Blood Institute. Pneumonia. 2016, September 26; Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu
6. Foster, G. Pegylated interferons for the treatment of chronic Hepatitis C. Drugs. 2010;70(2):147-165. doi:10.2165/11531990-000000000-00000
7. Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008, 28:1332-1343. doi: 10.1111/j.1478-3231.2008.01896.x
8. Alam, I., Lee, J., Cho, K. J., Han, K.R., Yang, J.M., Chung, M.S., & Kim, K. H. Crystal structures of murine norovirus-1 RNA-dependent RNA polymerase in complex with 2-thiouridine or ribavirin. Virology. 2012, 426: 143-151. https://dx.doi.org/10.1016/j.virol.2012.01.016
9. Johnson, ZL, Lee, JH, Lee, M, Kwon, DY, Hong, J, Lee, SY. Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters. eLife. 2014, 3:e03604. doi: 10.7554/eLife.03604.
10. Fujimoto T, Tomimatsu M, Iga D, Endo H, Otsuka K. Changes in the Th1/Th2 ratio during a 24-week course of an interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 2008, 23:E432- E437. doi: 10.1111/j.1440-1746.2008.05320.x
11. Feld, JJ, Nanda, S, Huang, Y, Chen, W, Cam, M, Pusek, SN, Schwigler, LM, Theodore, D, Zacks, SL, Liang, TJ, Fried, MW. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecule pathways for treatment response. Hepatol. 2007, 46(5): 1548-1563. doi: 10.1002/hep.21853
12. Thomas E, Feld JJ, Li QS, Hu ZY, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011, 53:32-41. doi: 10.1002/hep.23985
13. Shu QN, Nair V. Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med. Res. Rev. 2008, 28:219-232. doi: 10.1002/chin.200823265
14. Streeter, DG, Witkowski, JT, Khare, GP, Sidwell, RW, Bauer, RJ, Robins, RK, Simon, LN. Mechanisms of action of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole) a new broad spectrum antiviral agent. Proc. Natl. Acad. Sci. 1973, 70:1174-1178. PMID: 4197928
15. Kentsis, A, Topisirovic, I, Culjkovic, B, Shao, L, Borden, KLB. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the guanosine mRNA cap. Proc. Natl. Acad. Sci. 2004, 101:18105-18110. doi: 10.1073/pnas.0406927102
16. Graci, JD, Cameron, CE. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 2006, 16: 37-48. doi: 10.1002/rmv.483

Proteopedia Page Contributors and Editors (what is this?)

Edmond R Atalla, Taylor H. Derby, Alexander Berchansky